589 related articles for article (PubMed ID: 26318019)
1. Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression.
Chakera A; MacEwen C; Bellur SS; Chompuk LO; Lunn D; Roberts ISD
J Nephrol; 2016 Jun; 29(3):367-375. PubMed ID: 26318019
[TBL] [Abstract][Full Text] [Related]
2. Validation of the Oxford classification of IgA nephropathy.
Herzenberg AM; Fogo AB; Reich HN; Troyanov S; Bavbek N; Massat AE; Hunley TE; Hladunewich MA; Julian BA; Fervenza FC; Cattran DC
Kidney Int; 2011 Aug; 80(3):310-7. PubMed ID: 21544062
[TBL] [Abstract][Full Text] [Related]
3. IgA nephropathy clinicopathologic study following the Oxford classification: Progression peculiarities and gender-related differences.
Riispere Ž; Laurinavičius A; Kuudeberg A; Seppet E; Sepp K; Ilmoja M; Luman M; Kõlvald K; Auerbach A; Ots-Rosenberg M
Medicina (Kaunas); 2016; 52(6):340-348. PubMed ID: 27932191
[TBL] [Abstract][Full Text] [Related]
4. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments.
Coppo R; Troyanov S; Bellur S; Cattran D; Cook HT; Feehally J; Roberts IS; Morando L; Camilla R; Tesar V; Lunberg S; Gesualdo L; Emma F; Rollino C; Amore A; Praga M; Feriozzi S; Segoloni G; Pani A; Cancarini G; Durlik M; Moggia E; Mazzucco G; Giannakakis C; Honsova E; Sundelin BB; Di Palma AM; Ferrario F; Gutierrez E; Asunis AM; Barratt J; Tardanico R; Perkowska-Ptasinska A;
Kidney Int; 2014 Oct; 86(4):828-36. PubMed ID: 24694989
[TBL] [Abstract][Full Text] [Related]
5. A validation study of crescents in predicting ESRD in patients with IgA nephropathy.
Zhang X; Shi S; Ouyang Y; Yang M; Shi M; Pan X; Lv J; Wang Z; Ren H; Shen P; Wang W; Zhang H; Xie J; Chen N
J Transl Med; 2018 May; 16(1):115. PubMed ID: 29724226
[TBL] [Abstract][Full Text] [Related]
6. The Oxford Classification predictors of chronic kidney disease in pediatric patients with IgA nephropathy.
Fabiano RCG; Araújo SA; Bambirra EA; Oliveira EA; Simões E Silva AC; Pinheiro SVB
J Pediatr (Rio J); 2017; 93(4):389-397. PubMed ID: 28130969
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort.
Coppo R; Lofaro D; Camilla RR; Bellur S; Cattran D; Cook HT; Roberts IS; Peruzzi L; Amore A; Emma F; Fuiano L; Berg U; Topaloglu R; Bilginer Y; Gesualdo L; Polci R; Mizerska-Wasiak M; Caliskan Y; Lundberg S; Cancarini G; Geddes C; Wetzels J; Wiecek A; Durlik M; Cusinato S; Rollino C; Maggio M; Praga M; K Smerud H; Tesar V; Maixnerova D; Barratt J; Papalia T; Bonofiglio R; Mazzucco G; Giannakakis C; Soderberg M; Orhan D; Di Palma AM; Maldyk J; Ozluk Y; Sudelin B; Tardanico R; Kipgen D; Steenbergen E; Karkoszka H; Perkowska-Ptasinska A; Ferrario F; Gutierrez E; Honsova E
Pediatr Nephrol; 2017 Jan; 32(1):139-150. PubMed ID: 27557557
[TBL] [Abstract][Full Text] [Related]
8. The correlation analysis between the Oxford classification of Chinese IgA nephropathy children and renal outcome - a retrospective cohort study.
Wu H; Xia Z; Gao C; Zhang P; Yang X; Wang R; Wang M; Peng Y
BMC Nephrol; 2020 Jul; 21(1):247. PubMed ID: 32611399
[TBL] [Abstract][Full Text] [Related]
9. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation.
Shen XH; Liang SS; Chen HM; Le WB; Jiang S; Zeng CH; Zhou ML; Zhang HT; Liu ZH
J Nephrol; 2015 Aug; 28(4):441-9. PubMed ID: 25585823
[TBL] [Abstract][Full Text] [Related]
10. Clinical and histopathologic profile of patients with primary IgA nephropathy seen in a tertiary hospital in India.
Bagchi S; Singh G; Yadav R; Kalaivani M; Mahajan S; Bhowmik D; Dinda A; Agarwal SK
Ren Fail; 2016; 38(3):431-6. PubMed ID: 26837482
[TBL] [Abstract][Full Text] [Related]
11. Reproducibility of the Oxford classification of immunoglobulin A nephropathy, impact of biopsy scoring on treatment allocation and clinical relevance of disagreements: evidence from the VALidation of IGA study cohort.
Bellur SS; Roberts ISD; Troyanov S; Royal V; Coppo R; Cook HT; Cattran D; Arce Terroba Y; Asunis AM; Bajema I; Bertoni E; Bruijn JA; Cannata-Ortiz P; Casartelli D; Maria Di Palma A; Ferrario F; Fortunato M; Furci L; Gakiopoulou H; Galesic Ljubanovic D; Giannakakis K; Gomà M; Gröne HJ; Gutiérrez E; Asma Haider S; Honsova E; Ioachim E; Karkoszka H; Kipgen D; Maldyk J; Mazzucco G; Orhan D; Ozluk Y; Pantzaki A; Perkowska-Ptasinska A; Riispere Z; Soderberg MP; Steenbergen E; Stoppacciaro A; Sundelin Von Feilitzen B; Tardanico R
Nephrol Dial Transplant; 2019 Oct; 34(10):1681-1690. PubMed ID: 30561721
[TBL] [Abstract][Full Text] [Related]
12. Validation study of Oxford Classification of IgA Nephropathy: the significance of extracapillary hypercellularity and mesangial IgG immunostaining.
Ştefan G; Ismail G; Stancu S; Zugravu A; Andronesi A; Mandache E; Mircescu G
Pathol Int; 2016 Aug; 66(8):453-9. PubMed ID: 27439692
[TBL] [Abstract][Full Text] [Related]
13. Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis.
Xu K; Zhang L; Ding J; Wang S; Su B; Xiao H; Wang F; Zhong X; Li Y
J Nephrol; 2018 Apr; 31(2):279-286. PubMed ID: 29185209
[TBL] [Abstract][Full Text] [Related]
14. 30-year follow-up study of IgA nephritis in a Southeast Asian population: an evaluation of the Oxford histological classification
.
Woo KT; Lim CC; Foo MW; Loh HL; Jin AZ; Chin YM; Choo JC; Tan PH; Chow KY; Choong LH; Tan HK; Wong KS; Chan CM
Clin Nephrol; 2016 Nov; 86 (2016)(11):270-278. PubMed ID: 27641054
[TBL] [Abstract][Full Text] [Related]
15. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the oxford classification.
Shi SF; Wang SX; Jiang L; Lv JC; Liu LJ; Chen YQ; Zhu SN; Liu G; Zou WZ; Zhang H; Wang HY
Clin J Am Soc Nephrol; 2011 Sep; 6(9):2175-84. PubMed ID: 21852672
[TBL] [Abstract][Full Text] [Related]
16. IgA nephropathy: an update.
Soares MF; Roberts IS
Curr Opin Nephrol Hypertens; 2017 May; 26(3):165-171. PubMed ID: 28221174
[TBL] [Abstract][Full Text] [Related]
17. The MEST score provides earlier risk prediction in lgA nephropathy.
Barbour SJ; Espino-Hernandez G; Reich HN; Coppo R; Roberts IS; Feehally J; Herzenberg AM; Cattran DC; ;
Kidney Int; 2016 Jan; 89(1):167-75. PubMed ID: 26759049
[TBL] [Abstract][Full Text] [Related]
18. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.
Trimarchi H; Barratt J; Cattran DC; Cook HT; Coppo R; Haas M; Liu ZH; Roberts IS; Yuzawa Y; Zhang H; Feehally J; ;
Kidney Int; 2017 May; 91(5):1014-1021. PubMed ID: 28341274
[TBL] [Abstract][Full Text] [Related]
19. [The effect of endocapillary hypercellularity lesions on the renal prognosis and response to immunosuppressive therapy in IgA nephropathy].
Yang HY; Shi SF; Wang SX; Lyu JC; Zhang H
Zhonghua Nei Ke Za Zhi; 2020 Nov; 59(11):894-897. PubMed ID: 33120494
[TBL] [Abstract][Full Text] [Related]
20. Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores).
Schimpf JI; Klein T; Fitzner C; Eitner F; Porubsky S; Hilgers RD; Floege J; Groene HJ; Rauen T
BMC Nephrol; 2018 Nov; 19(1):328. PubMed ID: 30453889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
